Galectin Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference
08 April 2016 - 2:11AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today announced that Peter G. Traber,
M.D., the Company’s president, chief executive officer and chief
medical officer, will present at Needham & Company’s 15th
Annual Healthcare Conference on Wednesday, April 13, 2016 at 3:00
p.m. Eastern time. The conference is being held at the Westin Grand
Hotel in New York City on April 12-13, 2016.
A live webcast of the presentation may be
accessed on the company’s website at www.galectintherapeutics.com.
The webcast and presentation will be archived for 90 days following
the event.
About Galectin
TherapeuticsGalectin Therapeutics is developing promising
therapies for the treatment of fibrotic liver disease and cancer
based on the Company's unique understanding of galectin proteins,
which are key mediators of biologic function. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
Contacts:Jack Callicutt, Chief Financial
Officer(678) 620-3186ir@galectintherapeutics.com.
or
LHAKim Golodetz(212)
838-3777kgolodetz@lhai.com
Galectin Therapeutics and its associated logo is
a registered trademark of Galectin Therapeutics Inc.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2024 to May 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2023 to May 2024